top of page

NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CARCINOMA (MORPHEUS-NEO HCC)


This is a research study that is designed to test new drug combinations for treating liver cancer (hepatocellular carcinoma) in people who can have surgery to remove the cancer. The treatments being tested in this study are immunotherapy combinations. Immunotherapy helps the body’s immune system recognize and attack cancer cells. This is an open label, multi-centre and randomized phase 1b/II study.

Open-Label: Patients know which treatments are being given to them

Randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

For more information about the trial, click the link below:

Clinical Trial Site: Einstein


To see all available clinical trials click here.



Recent Posts

See All

NCI-2019-07694

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2) This is a research study called NAPOLI-2. It is designed to see

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatoce

NCI-2017-01380

OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy This research study is investigating a drug called

Comments


bottom of page